Literature DB >> 31585838

[An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants].

Manuel Sánchez Luna1, Alejandro Pérez Muñuzuri2, José Luis Leante Castellanos3, César W Ruiz Campillo4, Ester Sanz López1, Isabel Benavente Fernández5, María Dolores Sánchez Redondo6, Segundo Rite Gracia7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31585838     DOI： 10.1016/j.anpedi.2019.08.003

Source DB:  PubMed          Journal:  An Pediatr (Engl Ed)        ISSN： 2341-2879


× No keyword cloud information.
  3 in total

Review 1.  Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.

Authors:  Susanna Esposito; Bahaa Abu-Raya; Paolo Bonanni; Fabianne Cahn-Sellem; Katie L Flanagan; Federico Martinon Torres; Asuncion Mejias; Simon Nadel; Marco A P Safadi; Arne Simon
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

2.  Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children.

Authors:  Natividad Viguria; Ana Navascués; Regina Juanbeltz; Alberto Echeverría; Carmen Ezpeleta; Jesús Castilla
Journal:  Hum Vaccin Immunother       Date:  2021-01-27       Impact factor: 3.452

3.  Variation in the seasonality of the respiratory syncytial virus during the COVID-19 pandemic.

Authors:  Lorena Bermúdez Barrezueta; Vanesa Matías Del Pozo; Pablo López-Casillas; Marta Brezmes Raposo; María Gutiérrez Zamorano; María de la Asunción Pino Vázquez
Journal:  Infection       Date:  2022-03-22       Impact factor: 7.455
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.